Sugar and fat free: Ideal for those following strict diets and weight loss programs
The Glucagon-Like Peptide-1 (GLP-1) receptor agonist semaglutide was initially used for the treatment of type 2 diabetes and obesity [3, 4]
Compounded semaglutide, much of it low-cost and of questionable quality, has been spreading rapidly in the U.S., undercutting Novos pricing power
27 The plan had previously covered these drugs for weight loss, but noted that the cost was expected to grow to more than $1 billion by 2030, and roughly double the amount that enrolled members would have to pay in monthly premiums for their coverage
It does not distribute compounded drugs in bulk without prescriptions, a practice restricted to 503B outsourcing facilities
These drugs will only become more common and will increase in use